MVF FY26 Appendix 4E and Financial Report
Filed with ASX · · 98 pages · English
Underlying net profit after tax (NPAT) amounted to $16.1m which is below the guidance provided in June 2026 of between $17m to $18m. The result includes impact of the write-off of $1.4m (after tax) of prepaid assets. (1) The Directors consider EBITDA to be one of the key financial measures of the underlying performance of Monash IVF Group Limited. EBITDA is earnings before interest, tax, depreciat
Earlier from Monash IVF
- FY2026 Results release postponed to 31 August 2026
- Trading update
- Monash IVF rejects revised non-binding indicative proposal
- Revised NBIO to acquire MVF
- 1H26 Results Presentation
Later from Monash IVF
All Monash IVF news releasesFollow Monash IVF into a list and get an email when it puts out news.
Follow Monash IVF